Dose-response study of gevokizumab (S78989) 3mg, 10mg, 30mg or 60mg in patients with type 2 diabetes and diabetic kidney disease (DKD). A 66-week, international, multicenter, randomized, double-blind, parallel-group, placebo controlled study.
Phase of Trial: Phase II
Latest Information Update: 17 Dec 2016
At a glance
- Drugs Gevokizumab (Primary)
- Indications Diabetic nephropathies; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Servier
- 14 Nov 2015 Status changed from recruiting to completed as per European Clinical Trials Database record.
- 03 Apr 2015 New source identified and integrated : European clinical trials record EudraCT2013-003610-41
- 03 Apr 2015 New trial record